Price Chart

Executive Summary

Onconetix entered into two agreements on July 28, 2026: (1) a securities purchase agreement to sell 37,812 shares of Series F Convertible Preferred Stock to investors, and (2) an ELOC (equity line of credit) purchase agreement allowing the company to sell up to $750M of common stock to a single investor, subject to a 19.99% cap. The Series F preferred sale provides immediate capital, but the ELOC creates massive potential dilution—up to 750M shares reserved—for a company with a $3M market cap and only ~3.9M shares outstanding. The combination of a dilutive equity line and a preferred stock issuance signals severe financial distress and a desperate need for capital, making this filing highly bearish.

Key Financial Metrics

Key Facts

• Onconetix entered into an ELOC purchase agreement to sell up to $750M of common stock, capped at 19.99% of outstanding shares unless stockholder approval is obtained.
• The company entered into a securities purchase agreement to sell 37,812 shares of Series F Convertible Preferred Stock.
• The company reserved 750,000,000 shares of common stock for the ELOC, dwarfing the ~3.9M shares currently outstanding.
• The Series F preferred stock is convertible into common shares, adding further dilution.
• Up to 15% of ELOC proceeds are committed to redeeming the Series F Preferred Stock, indicating a circular capital structure.
• The company has a market cap of only ~$3M, making the potential dilution from the ELOC extreme relative to its size.
• The company's historical performance shows an average T+20 return of -32.52% on prior reports, with a 33% win rate.
• The company's stock is listed on Nasdaq with a $0.10 minimum price condition for ELOC draws, suggesting the stock is near penny-stock territory.

Financial Impact

Massive potential dilution: up to 750M shares reserved for the ELOC vs. ~3.9M shares outstanding. Immediate capital from Series F preferred sale of 37,812 shares at an undisclosed price.

Risk Factors

• Extreme dilution from the ELOC and preferred stock conversion.
• Potential Nasdaq delisting if the stock price falls below $0.10 or market cap falls below minimum requirements.
• Circular capital structure where ELOC proceeds are used to redeem preferred stock, suggesting no real operational funding.
• Historical performance shows the stock has been a consistent loser, with a 33% win rate on prior reports.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

US Market Status